Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
PR Newswire•06/11/2026•06:47 ET
24
Key Highlights
- ➤Lilly and Hims & Hers agree to expand FDA-approved Zepbound and Foundayo access
- ➤Foundayo self-pay pricing starts at $149 per month
- ➤Zepbound self-pay pricing starts at $299 per month
- ➤Hims & Hers pledges not to offer compounded copies of Lilly’s GLP-1s
Expert Statements
Ilya Yuffa, Executive Vice President and President, Lilly USA and Global Customer Capabilities, Eli Lilly and Company
“At Lilly, we are always looking for new ways to help more people get the medicines they need, and that means meeting patients where they already are”
Ilya Yuffa, Executive Vice President and President, Lilly USA and Global Customer Capabilities, Eli Lilly and Company
“Millions of people turn to Hims & Hers for their care, and through this agreement, those patients now have a simple, more direct way to get FDA-approved Lilly medicine at an affordable price if prescribed.”
Andrew Dudum, co-founder and CEO of Hims & Hers
“Lilly is one of the most innovative pharmaceutical companies in history, and I'm incredibly proud that Hims & Hers is a part of making sure more people can access the medicines they've created”
Andrew Dudum, co-founder and CEO of Hims & Hers
“By working together, we're not just reaching more people with obesity with seamless, personal access to FDA-approved Lilly medicine. We're showing the industry what innovators can achieve for customers everywhere when we work together to make the world well.”
Lilly and Hims & Hers expand access to FDA-approved Lilly medicines PR Newswire
Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platform
Get started
Create a free account to read the full story.